MSK Announced as M&A Advisor Awards Finalist
MSK is pleased to announce that The M&A Advisor, recognized as the world’s premier “think tank” and leadership organization for mergers & acquisitions, restructuring and financing professionals, has named MSK as a Finalist in its 2016 M&A Advisor Deal of the Year Awards, in the Healthcare and Life Sciences Deal of the Year (under $100 Million) and Cross Border Deal of the Year ($50 - $100 Million) categories, for MSK’s representation of VBI Vaccines Inc. (Nasdaq: VBIV) in the Acquisition of VBI Vaccines by SciVac Therapeutics. The winners will be announced at the 15th Annual M&A Advisor Awards Gala on Wednesday, November 9th at the New York Athletic Club.
This complex merger of two listed companies, spanning three countries, combined VBI Vaccines Inc. with SciVac Therapeutics Inc. (formerly, TSX: VAC), creating a commercial-stage biopharmaceutical company developing a next generation pipeline of vaccines to address unmet needs in infectious disease and immuno-oncology. The merger posed numerous challenges and provided significant benefits to the parties, recognized by The M&A Advisor as qualifying factors. The merged company is listed on The Nasdaq Capital Market under the symbol “VBIV”.
"We are honored to receive The M&A Advisor’s recognition for our role in this industry-impacting merger alongside so many notable names and transactions," stated Kevin Friedmann, Chairman of MSK's Corporate & Business Transactions Department and member of MSK's Governing Board. “VBI is a long-time client. Having represented VBI in its going public transaction in 2014, we are thrilled to see its most recent success recognized so publicly," said Mr. Friedmann in closing.
For a detailed list of all of the Award Finalists for the 15th Annual M&A Advisor Awards, please CLICK HERE.
